Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane for Doxorubicin-Associated Cardiac Dysfunction in Breast Cancer
NCT03934905Phase 2Recruiting
- Sponsor
- Texas Tech University Health Sciences Center
- Start
- Jun 2022
- Primary completion
- Nov 2028
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cardiotoxicity comparing Sulforaphane with Placebo (2 arms). Primary endpoint: Change in cardiac function at 1 year. Started Jun 2022; status: recruiting.
02
Drugs
sulforaphane
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT03934905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934905.